The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals

American Journal of Epidemiology

Volumn 174, Issue 8, 2011, Pages 949-957

  Ito, Hiroki ^a   Pacold, Ivan V ^a   Durazo Arvizu, Ramon ^a   Liu, Kiang ^b   Shilipak, Michael G ^c   Goff Jr , David C ^d   Tracy, Russell P ^e   Kramer, Holly ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

cardiovascular diseases; creatinine; cystatin C; risk model

Indexed keywords

CREATININE; CYSTATIN C;

CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIABETES; MATHEMATICAL ANALYSIS; NUMERICAL MODEL; PEPTIDE; RISK FACTOR; SERUM;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE MARKER; ETHNICITY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; STROKE;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CREATININE; CYSTATIN C; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT;

EID: 80054062629     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr185     Document Type: Article

References (29)

1. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847. (Pubitemid 28213628)
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
3. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. (Pubitemid 351640675)
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-2169. (Pubitemid 37337595)
5. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15(5):1307-1315. (Pubitemid 38526012)
6. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation. Ann Intern Med. 2003;139(2):137-147.
7. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100. (Pubitemid 41623371)
8. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29-34. (Pubitemid 30432560)
9. Seliger SL, Longstreth WT Jr, Katz R, et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol. 2005;16(12): 3721-3727. (Pubitemid 46211294)
10. Ix JH, Katz R, De Boer IH, et al. Association of chronic kidney disease with the spectrum of ankle brachial index: The CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2009; 54(13):1176-1184.
11. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049-2060. (Pubitemid 40664306)
12. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(2):173-179. (Pubitemid 46105715)
13. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Cardiovascular Health Study. Ann Intern Med. 2005;142(7): 497-505.
14. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1): 85-97. (Pubitemid 47016250)
15. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156(9):871-881. (Pubitemid 35215769)
16. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59(1):1-8. (Pubitemid 29133539)
17. Burnham KP, Anderson DR. Model Selection and Inference: A Practical Information-Theoretic Approach. New York, NY: Springer-Verlag; 1998.
18. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference and Prediction. New York, NY: Springer-Verlag; 2001.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-845.
20. Cook NR, Buring JE, Ridker PM. The effect of including Creactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145(1):21-29. (Pubitemid 46780601)
21. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007; 115(7):928-935. (Pubitemid 46294733)
22. Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med. 2008; 149(10):751-760.
23. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172. (Pubitemid 351193639)
24. Weiner DE, Tighiouart H, Griffith JL, et al. Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am J Med. 2007;120(6):552.e1- 552.e8.
25. Hallan S, Astor B, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs. younger individuals: the HUNT II Study. Arch Intern Med. 2007;167(22):2490-2496. (Pubitemid 350254909)
26. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 2006; 166(13):1368-1373. (Pubitemid 44036348)
27. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study [electronic article]. BMJ. 2009; 338a3083. (doi:10.1136/bmj.a3083).
28. Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007;35(9):2052-2056. (Pubitemid 47326440)
29. Marcin JP, Romano PS. Size matters to a model's fit. Crit Care Med. 2007;35(9):2212-2213. (Pubitemid 47326466)